Local induction of programmed death ligand 1 (PD-L1) in the tumour microenvironment, increased T cell clonal expansion, decreased PD-1 expression in peripheral blood T cells, and decreased monocyte numbers were more frequently observed in the neoadjuvant group in patients treated. This evidence concerns the gene PDCD1 and neoplasm.